Phase 4 N=15 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=53 Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
Breast Cancer
Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients
Phase 3 N=27 Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Clostridium Enterocolitis · Pseudomembranous Colitis
Primary: Nitazoxanide — 27 participants
Phase 2 N=100 Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Chemotherapeutic Agent Toxicity · Colorectal Cancer · Diarrhea
Primary: Number of Participants With Grade 3/4 Diarrhea — 27; 26; 7; 3 Participants
Phase 3 N=87 Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
Diarrhea · Gastrointestinal Complications · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT) — 10; 10; 13; 15 Participants — p=0.41
Early Phase 1 N=66 Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
Antibiotic-associated Diarrhea
Primary: Level of Fecal Short-chain Fatty Acid (SCFA) Acetate — 53.1; 45.2; 42.3; 38.1 micromolar (μM)
Early Phase 1 N=118 Mechanisms of Probiotics and Antibiotic-Associated Diarrhea
Antibiotic-associated Diarrhea
Primary: Change From Baseline Levels of Fecal Short-chain Fatty Acid (With a Particular Focus on Acetate) — 23.55; -13.9; -19.5; 7.25 micromolar
Phase 2 N=34 Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
Recurrent Clostridium Difficile Infection
Primary: Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660 — 10 number of reported SAEs through 56 days
N/A N=10 Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)
Diarrhea · Clostridium Difficile
Primary: Pharmacokinetics of Tigecycline Along With Standard Treatments for Clostridium Difficile — 0.18 milligrams/liter
Phase 4 N=19 Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
Anticholinergics Toxicity
Primary: Comparison of RASS Score Between Physostigmine and Lorazepam: Before Bolus — 1.5; 1 score on a scale
Phase 4 N=33 Impact of Oral Antibiotic Treatment on C. Difficile
C. Difficile · Diarrhea · Enterocolitis
Primary: Change in Total Median Total Colony Forming Units (CFU) of C. Difficile Identified in the Hospital Room Environment for Each Antibiotic Treatment Group. — 56; 33; 149; 7…
Phase 4 N=93 Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
Chronic Diarrhea of Unknown Origin
Primary: Number of Participants With a 50 Percent Decrease in Mean Stool Count — 17 Participants
N/A N=101 Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea
Diarrhoea
Primary: Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1) — 21.30 hours
Phase 4 N=9 C. Difficile and Ursodiol
Diarrhea
Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants
Phase 2 N=150 Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera
Cholera
Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003
Phase 2 N=120 Traveler's Diarrhea (TD) Automated Process
Prevention of Travelers' Diarrhea
Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer
Phase 2 N=144 Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea
Diarrhoea;Acute
Primary: Reduction in Frequency of Defecation to 3 Times Per Day — 118; 24 Participants
Phase 3 N=237 A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Clostridium Infections · Diarrhea
Primary: Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal…
Phase 2 N=30 Use of Pyridostigmine for Constipation in Diabetics
Constipation · Diabetes Mellitus · Colonic Transit
Primary: Colonic Geometric Center at 24 Hours (GC24) Measured by Scintigraphy — 1.96; 1.98; 2.45; 1.84 units on a scale — p=<0.01
Phase 3 N=139 Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Chemotherapy-induced Diarrhea
Primary: Percentage of Participants Developing Diarrhea (Grade 1 to 4) — 76.1; 78.9 Percentage of Participants
Phase 3 N=606 Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT) — 79.0; 83.6 Percentage of participants
Phase 2 N=200 Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
Clostridium Infections
Primary: Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) — 7; 25 Participants
Phase 3 N=40 ADAM-Afatinib Diarrhea Assessment and Management
Carcinoma, Non-Small-Cell Lung
Primary: Occurence of CTCAE Grade >= 2 Diarrhea — 72.20; 31.80 Percentage of participants
N/A N=214 Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea
Antibiotics Associated Colitis · Pulmonary Infection
Primary: Presence of AAD — 12 participants — p=<0.05
Phase 2 N=565 Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…
Phase 2 N=11 Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
HER2-positive Breast Cancer · Breast Adenocarcinoma · Stage II Breast Cancer AJCC v6 and v7
Primary: Percentage of Participants With Grade 3 or Greater Diarrhea — 29; 50 percentage of participants
Phase 3 N=69 Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
Rectal Cancer
Primary: Number of Participants Who Completed MSKCC Bowel Function Instrument (BFI Score) in Patients Following Anterior Resection (AR) or Sphincter Preserving Surgery (SPS) for…
Phase 2 N=9 Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Clostridium Difficile Infection · Hematologic Diseases · Bone Marrow Transplant
Primary: Changes in Clostridium Difficile Bacterial Loads in the Stool — 62102500.00; 40000000.00; 7752750.00; 185000.00 CFUs
Phase 2 N=40 Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea
Infectious Diarrhoea
Primary: Time to Last Unformed Stool (TLUS) — 59.3; 51.4; 57.4 hours
N/A N=11,157 Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Overactive Bladder
Primary: Confirmation of the Incidence of All Treatment Related Adverse Events (TRAEs). — 984 participants